{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:19:03Z","timestamp":1793830743230,"version":"4.6.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900537"],"award-info":[{"award-number":["81900537"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["M22030-7222093"],"award-info":[{"award-number":["M22030-7222093"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["Z201100005520046"],"award-info":[{"award-number":["Z201100005520046"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["Z211100002921059"],"award-info":[{"award-number":["Z211100002921059"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special Fund","doi-asserted-by":"publisher","award":["2020-1-2181"],"award-info":[{"award-number":["2020-1-2181"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.heliyon.2023.e13113","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T02:55:44Z","timestamp":1674183344000},"page":"e13113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis"],"prefix":"10.1016","volume":"9","author":[{"given":"Lili","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.heliyon.2023.e13113_bib1","doi-asserted-by":"crossref","first-page":"e00046","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13113_bib2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2471\/BLT.18.219469","article-title":"Countdown to 2030: eliminating hepatitis B disease, China","volume":"97","author":"Liu","year":"2019","journal-title":"Bull. World Health Organ."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13113_bib3","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13113_bib4","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2023.e13113_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13113_bib6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"Younossi","year":"2020","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13113_bib7","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia","volume":"67","author":"Fan","year":"2017","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13113_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes: HEPATOLOGY, Vol. XX, No. X 2016","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13113_bib9","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13113_bib10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/liv.13933","article-title":"Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: a population-based cohort study","volume":"39","author":"Zhu","year":"2019","journal-title":"Liver Int."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e13113_bib11","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.14309\/ajg.0000000000001257","article-title":"Hepatic steatosis and steatohepatitis in a large North American cohort of adults with chronic hepatitis B","volume":"116","author":"Khalili","year":"2021","journal-title":"Am. J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e13113_bib12","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/apt.16595","article-title":"Systematic review with meta\u2010analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B","volume":"54","author":"Zheng","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13113_bib13","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hep.28917","article-title":"Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study","volume":"65","author":"Joo","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2023.e13113_bib14","doi-asserted-by":"crossref","unstructured":"Cheng YL, Wang YJ, Kao WY, et al. Inverse Association between Hepatitis B Virus Infection and Fatty Liver Disease: A Large-Scale Study in Populations Seeking for Check-Up. Wang Y, ed. PLoS ONE. 2013;8(8):e72049. doi:10.1371\/journal.pone.0072049.","DOI":"10.1371\/journal.pone.0072049"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13113_bib15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2011.09.013","article-title":"Hepatitis B virus infection and fatty liver in the general population","volume":"56","author":"Wong","year":"2012","journal-title":"J. Hepatol."},{"issue":"21","key":"10.1016\/j.heliyon.2023.e13113_bib16","first-page":"S0929","article-title":"Hepatic steatosis and development of type 2 diabetes: impact of chronic hepatitis B and viral specific factors","volume":"8","author":"Yu","year":"2021","journal-title":"J Formos Med Assoc. Published online November"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e13113_bib17","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s10620-014-3180-9","article-title":"Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors","volume":"59","author":"Wang","year":"2014","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.heliyon.2023.e13113_bib18","series-title":"Metabolic Syndromes, Hepatitis B Virus (HBV), and Hepatitis C Virus as Three Factors Involved in the Development of Hepatic Steatosis: a Systematic Review and Meta-Analysis","author":"Keikha","year":"2022"},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13113_bib19","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20211769","article-title":"Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan","volume":"41","author":"Jiang","year":"2021","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13113_bib20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jvh.13014","article-title":"Chronic hepatitis B virus infection and risk of dyslipidaemia: a cohort study","volume":"26","author":"Joo","year":"2019","journal-title":"J. Viral Hepat."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13113_bib21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.metabol.2012.07.022","article-title":"Combined effects of hepatitis B virus infection and elevated alanine aminotransferase levels on dyslipidemia","volume":"62","author":"Liu","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.heliyon.2023.e13113_bib22","article-title":"Multifaceted interaction between hepatitis B virus infection and lipid metabolism in hepatocytes: a potential target of antiviral therapy for chronic hepatitis B","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Microbiol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13113_bib23","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1128\/JVI.02604-15","article-title":"Hepatitis B virus X protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein. Sandri-goldin RM","volume":"90","author":"Wu","year":"2016","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13113_bib24","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1053\/j.gastro.2007.03.039","article-title":"Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPAR\u03b3","volume":"132","author":"Kim","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13113_bib25","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jmb.2010.02.016","article-title":"HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-\u03baB-Dependent pathways","volume":"397","author":"Kim","year":"2010","journal-title":"J. Mol. Biol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13113_bib26","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/sj.ijo.0803479","article-title":"Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?","volume":"31","author":"Chu","year":"2007","journal-title":"Int. J. Obes."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13113_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10620-012-2343-9","article-title":"Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without","volume":"58","author":"Chu","year":"2013","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13113_bib28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/infdis\/jiaa739","article-title":"Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B","volume":"224","author":"Li","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13113_bib29","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","article-title":"Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B","volume":"73","author":"Mak","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2023.e13113_bib30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/JHC.S355540","article-title":"Impact of PNPLA3 p.I148M and hepatic steatosis on long-term outcomes for hepatocellular carcinoma and HBsAg seroclearance in chronic hepatitis B","volume":"ume 9","author":"Hsueh","year":"2022","journal-title":"JHC"},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13113_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14899","article-title":"Role of hepatosteatosis in HBsAg seroconversion in HBeAg\u2010negative chronic hepatitis B patients","volume":"75","author":"Bacaks\u0131z","year":"2021","journal-title":"Int. J. Clin. Pract."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e13113_bib32","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jvh.13594","article-title":"No influence of hepatic steatosis on the 3\u2010year outcomes of patients with quiescent chronic hepatitis B","volume":"28","author":"Chang","year":"2021","journal-title":"J. Viral Hepat."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13113_bib33","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12072-018-9877-7","article-title":"Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model","volume":"12","author":"Hu","year":"2018","journal-title":"Hepatol Int"},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13113_bib34","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1111\/j.1440-1746.2012.07268.x","article-title":"Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model: steatosis reduces Hepatitis B virus replication","volume":"27","author":"Zhang","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13113_bib35","first-page":"332","article-title":"[Model building-up and observation on the mouse carried chronic hepatitis B and nonalcoholic fatty liver disease]","volume":"27","author":"Lu","year":"2013","journal-title":"Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi"},{"key":"10.1016\/j.heliyon.2023.e13113_bib36","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1016\/S0168-8278(22)00890-X","article-title":"Enhanced T cell responses in patients and mouse model of hepatitis B and comorbid non-alcoholic fatty liver disease","volume":"77","author":"Patel","year":"2022","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13113_bib37","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.15(5)2015.27909","article-title":"Saturated fatty acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic fatty liver disease by toll-like receptor 4-mediated innate immune response","volume":"15","author":"Zhang","year":"2015","journal-title":"Hepat. Mon."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13113_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034198","article-title":"Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. Jhaveri R","volume":"7","author":"Jin","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13113_bib39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3350\/cmh.2018.0054","article-title":"Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir","volume":"25","author":"Kim","year":"2019","journal-title":"Clin. Mol. Hepatol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13113_bib40","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/liv.15086","article-title":"Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection","volume":"42","author":"Kim","year":"2022","journal-title":"Liver Int."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e13113_bib41","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1016\/j.transproceed.2015.10.023","article-title":"Hepatic steatosis as a predictive factor of antiviral effect of pegylated interferon therapy in patients with hepatitis B","volume":"47","author":"Gong","year":"2015","journal-title":"Transplant. Proc."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e13113_bib42","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiab241","article-title":"Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B","volume":"224","author":"Hsu","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13113_bib43","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/liv.14415","article-title":"Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients","volume":"40","author":"Li","year":"2020","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13113_bib44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5152\/tjg.2015.150348","article-title":"Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir","volume":"27","author":"Ceylan","year":"2016","journal-title":"Turk. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13113_bib45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.mcg.0000225586.78330.60","article-title":"Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection","volume":"41","author":"Cindoruk","year":"2007","journal-title":"J. Clin. Gastroenterol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13113_bib46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12876-020-01289-w","article-title":"Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Gastroenterol."},{"issue":"11\u201312","key":"10.1016\/j.heliyon.2023.e13113_bib47","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.nut.2016.04.001","article-title":"Effects of nucleos(t)ide analogs on body composition in HBV-infected men: an age- and BMI-matched, cross-sectional study","volume":"32","author":"Yao","year":"2016","journal-title":"Nutrition"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13113_bib48","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/apt.14218","article-title":"Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers","volume":"46","author":"Shaheen","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2023.e13113_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/liv.15261","article-title":"Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment\u2010na\u00efve chronic hepatitis B","author":"Lim","year":"2022","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13113_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261760","article-title":"Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. Chemin I","volume":"17","author":"Suzuki","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2023.e13113_bib51","article-title":"Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide","author":"Yeh","year":"2021","journal-title":"J. Formos. Med. Assoc."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13113_bib52","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jgh3.12481","article-title":"Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients","volume":"5","author":"Lee","year":"2021","journal-title":"JGH Open"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13113_bib53","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3350\/cmh.2021.0314","article-title":"Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis","volume":"28","author":"Jeong","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13113_bib54","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cgh.2021.04.045","article-title":"Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate","volume":"20","author":"Byun","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13113_bib55","first-page":"733","article-title":"Cardiovascular risk factors and prevention: a perspective from developing countries","volume":"37","author":"Teo","year":"2021","journal-title":"Can. J. Cardiol."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e13113_bib56","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1080\/10408398.2020.1764487","article-title":"Dietary habits, lipoprotein metabolism and cardiovascular disease: from individual foods to dietary patterns","volume":"61","author":"Gomez-Delgado","year":"2021","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.heliyon.2023.e13113_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr. Pract."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13113_bib58","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2017.09.044","article-title":"Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B","volume":"16","author":"Seto","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e13113_bib59","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jfma.2020.05.027","article-title":"Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan","volume":"119","author":"Su","year":"2020","journal-title":"J. Formos. Med. Assoc."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e13113_bib60","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/jvh.13095","article-title":"Fibrosis evolution in chronic hepatitis B e antigen\u2010negative patients across a 10\u2010year interval","volume":"26","author":"Mak","year":"2019","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.heliyon.2023.e13113_bib61","article-title":"Application of fatty liver inhibition of progression algorithm and steatosis, activity, and fibrosis score to assess the impact of non-alcoholic fatty liver on untreated chronic hepatitis B patients","volume":"11","author":"Huang","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13113_bib62","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/liv.13271","article-title":"The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response","volume":"37","author":"Charatcharoenwitthaya","year":"2017","journal-title":"Liver Int."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13113_bib63","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/jvh.13361","article-title":"Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B","volume":"27","author":"Wong","year":"2020","journal-title":"J. Viral Hepat."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e13113_bib64","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/00325481.2016.1221733","article-title":"Is there an influence of hepatic steatosis on fibrosis and necroinflammation in young patients with chronic viral hepatitis B?","volume":"128","author":"Karacaer","year":"2016","journal-title":"PGM (Postgrad. Med.)"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13113_bib65","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/jvh.12766","article-title":"Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study","volume":"25","author":"Hui","year":"2018","journal-title":"J. Viral Hepat."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13113_bib66","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1478-3231.2009.01976.x","article-title":"Hepatic steatosis and fibrosis in young men with treatment-na\u00efve chronic hepatitis B","volume":"29","author":"Yun","year":"2009","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13113_bib67","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejim.2014.12.001","article-title":"Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease","volume":"26","author":"Pais","year":"2015","journal-title":"Eur. J. Intern. Med."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e13113_bib68","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/MCG.0000000000001217","article-title":"Radiologic nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with suppressed chronic hepatitis B","volume":"54","author":"Cho","year":"2020","journal-title":"J. Clin. Gastroenterol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13113_bib69","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/jgh.13536","article-title":"Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B: steatosis and cancer in hepatitis B","volume":"32","author":"Chan","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13113_bib70","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3350\/cmh.2018.0040","article-title":"Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"25","author":"Lee","year":"2019","journal-title":"Clin. Mol. Hepatol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13113_bib71","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s12072-021-10218-2","article-title":"Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection","volume":"15","author":"Mak","year":"2021","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13113_bib72","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3350\/cmh.2016.0021","article-title":"Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B","volume":"22","author":"Lee","year":"2016","journal-title":"Clin. Mol. Hepatol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023003201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023003201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:39:38Z","timestamp":1765359578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023003201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2405844023003201"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e13113","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e13113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e13113"}}